ClinicalTrials.gg
WithdrawnNCT03812874Updated Oct 2, 2026

A Study of PTX-9908 Injection for Non-resectable HCC With TACE

A Phase 1/2 interventional study of PTX-9908 Injection and Placebo in Carcinoma, Hepatocellular, sponsored by TCM Biotech International Corp.. Withdrawn at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by TCM Biotech International Corp. · Phase 1/2, Interventional, and Treatment

How we know

Why this study was withdrawn
Due to business considerations and challenges in participant recruitment, the Sponsor has decided to discontinue the study.
Updated Oct 2, 2026Now WithdrawnPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 273 studies in Carcinoma, Hepatocellular with a site in Taiwan — 46 open to participants now, 69 under way, 11 of them phase 3. Carcinoma, Hepatocellular · Taiwan.

Enrollment
222nd of 224
0 · median 98
Started
2020
with 9 others
Phase 1/2
34 of 273
8 open now
Registered
177th of 273
by date

Among the 273 studies in Carcinoma, Hepatocellular with a site in Taiwan, this one is the 222nd largest by enrollment of the 224 interventional ones that give a count, is one of 10 that started in 2020, is one of 34 in phase 1/2, and was the 177th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

46 of the 273 studies in Carcinoma, Hepatocellular with a site in Taiwan are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 273 studies in Carcinoma, Hepatocellular with a site in Taiwan, or all of them as a file.
02

Study summary

This is a multicenter, Phase I/II study in patients with non-resectable hepatocellular carcinoma following TACE treatment.

Phase I (Open-label dose escalation)

This study will be an open-label study with an Accelerated Phase and a Standard Phase. For the Accelerated Phase of the study, one patient per dose level (1 mg/kg, and 2 mg/kg) is planned. For the dose levels in the standard phase (4 mg/kg, 8 mg/kg and 16 mg/kg), it will follow the Fibonacci's rule of 3 + 3 design. All eligible patients who have received TACE treatment and recovered well, will be administrated PTX-9908 Injection intravenously one dose per day for 5 days on Week 1 (excludes weekends and public holidays), and one dose per week (on Day 8, Day 15, and Day 22) for 3 consecutive weeks. The 4-week treatment period, will be followed by a 2-week follow-up period.

Phase II (Randomized placebo controlled dose expansion)

The objective of phase II is to further evaluate the safety, tolerability and antitumor activity of PTX-9908 Injection for patients with non-resectable hepatocellular carcinoma following TACE treatment. Approximately 24 eligible patients who have received TACE treatment and recovered, will be randomized to PTX-9908 Injection using the predetermined dose in phase I or the vehicle placebo in a 2:1 ratio. PTX-9908 Injection or placebo will be administered intravenously one dose per day for 5 days in Week 1 (excludes weekends and public holidays), and one dose per week till Week 12 (Day 78). The 12-week treatment period, will be followed by a 2-week follow-up period.

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Unresectable hepatocellular carcinoma and at intermediate-stage HCC (BCLC stage B or class A/B with large or multifocal HCC, no vascular invasion, or extrahepatic spread) with completed TACE procedure in 4 weeks before day 1 of study intervention infusion.
  2. Recovered from TACE treatment and procedure related toxicities including /AST and within normal limit or reference numeric value (reference value is defined as the test value before TACE procedure).
  3. (Eastern Cooperative Oncology Group) performance status \< 2.
  4. Have adequate organ and marrow function as defined below:

    1. > 1,200/µL
    2. > 9 g/dL
    3. > 100,000/µL
    4. Total bilirubin \< 2 X
  5. Have adequate kidney function as estimated (eGFR) > 60 mL/min/1.73m2
  6. A negative pregnancy test at screening. This applies to any female patient with .
  7. Agree to use adequate after signing form, during the duration of study participation and for at least 4-weeks after completion or withdrawal from the study. This applies to any female patient with childbearing potential and any male patient whose female partner has childbearing potential.

    Acceptable contraceptive methods include:

    1. Established use of oral, injected or implanted hormonal methods of contraception
    2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
    3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) >=20 years of age. (Note: In Taiwan, age of majority recognized in law is 20 years of age)
  8. >=20 years of age. (Note: In Taiwan, age of majority recognized in law is 20 years of age)
  9. Anticipated of >= 6 months at assessment during screening.
  10. Ability to understand and have signed a written informed consent document.

Exclusion criteria

Exclusion Criteria:

  1. 1. Patient with B8-9.
  2. Patient who has had anti-cancer therapy including surgery, radiotherapy, immunotherapy, or chemotherapy (except in TACE regimen) within 4 weeks prior to the screening visit.
  3. Patient who has received any other agents within 4 weeks prior to the screening visit.
  4. Patient who has not recovered from the side effects of the earlier investigational agent or had anti-cancer therapy including surgery, radiotherapy, immunotherapy, or chemotherapy.
  5. Patient with known , or epidural (unless treated and well controlled for >= 3 months).
  6. Patient with prior history of co-, except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of the breast, and basal cell/squamous cell skin cancer.
  7. Patient with history of myocardial infarction or uncontrolled cardiac dysfunction, or unstable arrhythmia or symptomatic peripheral arterial vascular disease.
  8. Patient with history of positive serology for (HIV).
  9. Patient with active, uncontrolled bacterial, viral, or fungal infections, which require systemic therapy.
  10. Patient with poor liver function as indicated by serum > 2 mg/dL, Child-Pugh Class C, severe coagulopathy ( > 2) not correctable with vitamin K, or active hepatic encephalopathy.
  11. Patient with known allergic reactions to biological agent or polypeptides similar to PTX-9908 Injection.
  12. Woman who is pregnant or nursing.
  13. Patient with concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study.
  14. Patient with unwillingness or inability to comply with the study protocol for any reason.
  15. A marked baseline prolongation of /QTc interval (e.g., repeated demonstration of a QTc interval >480 milliseconds (ms) ( grade 1) using Frederica's QT correction formula
  16. A history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  17. The use of concomitant medications that prolong the QT/QTc interval
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    PTX-9908 Injection group

    IV injection.

    Drug: PTX-9908 Injection

  • Placebo comparator
    Placebo/Vehicle group

    IV injection

    Drug: PTX-9908 Injection · Drug: Placebo

Interventions

  • DrugPTX-9908 Injection

    Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg. Frequency: Phase I: one dose per day for 4 consecutive weeks (20 doses). Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses). Duration: 4 weeks (Phase I) and 12 weeks (Phase II).

  • DrugPlacebo

    water for injection Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses). Duration: 12 weeks (Phase II)

06

What researchers measure

Primary outcomes

  1. Safety as measured by the number and severity of Adverse Events

    Time frame: Week 1 - Week 8 (Phase I)/Week 16 (Phase II)

  2. Safety as measured by number of participants with a dose limiting toxicity (DLT)

    Any of the following, if judged to be associated with PTX-9908 Injection or the combination of TACE with PTX-9908 Injection (i.e., with possible causality) that occur within the DLT evaluation window, will be considered as a DLT. 1. All Grade 4 (i.e., life-threatening) non-hematological and hematological toxicities (except for Grade 4 lymphopenia). 2. Grade 3 anemia with clinically significant bleeding 3. All grades of febrile neutropenia. 4. All Grade 3 non-laboratory/non-hematologic treatment-emergent adverse events, with the exception for nausea, vomiting, or diarrhea that resolves within 3 days. 5. Grade 3 thrombocytopenia with clinically significant bleeding is a DLT. 6. Grade 3 cytokine release syndrome of any duration is a DLT. 7. Grade 3 laboratory adverse events that are judged by the investigator as clinically significant.

    Time frame: Week 1 - Week 6 (Phase I only)

Secondary outcomes

  1. Recommended Phase 2 Dose (RP2D)

    The RP2D was based on the highest dose in which 0/6 or 1/6 participants experienced DLT with at least 2 out of no more than 6 participants experiencing DLT at the next higher dose level, and the assessment of any relevant chronic toxicity.

    Time frame: Week 1 - Week 6 (Phase I only)

  2. Maximum Plasma Concentration (Cmax) of single-dose and repeat-dose of PTX-9908 Injection

    Pharmacokinetics (PK) is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Cmax=maximum observed plasma concentration of PTX-9908 Injection administered with IV dose derived from plasma concentration versus time data.

    Time frame: Day 1, Day 5, Day 8, Day 15, and Day 26 in Phase I and Phase II

  3. Terminal Half-life (T-Half) of single-dose and repeat-dose of PTX-9908 Injection

    PK is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. T-Half=terminal-phase elimination half-life in plasma of PTX-9908 Injection administered with IV.

    Time frame: Day 1, Day 5, Day 8, Day 15, and Day 26 in Phase I and Phase II

  4. Overall Tumor Response

    Number of participants with a best overall tumor response of complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD). Overall tumor response will be assessed using contrast-enhanced CT imaging according to mRECIST criteria following the 1.1 release of RECIST.

    Time frame: Week 1 - Week 16 (Phase II)

  5. Response of target hepatic lesions in embolized territory

    Number of participants with hepatic lesion in embolized territory of complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD). Tumor response will be assessed using contrast-enhanced CT imaging according to mRECIST criteria following the 1.1 release of RECIST

    Time frame: Week 1 - Week 16 (Phase II)

  6. To evaluate overall time-to-progression

    Time to progression (TPP) will start from TACE administration to radiological progression. Definition of progression is based on the mRECIST criteria.

    Time frame: Week 1 - Week 16 (Phase II)

  7. To evaluate change in AFP levels.

    Time frame: Week 1 - Week 16 (Phase II)

07

Study locations

1 site
  • National Taiwan University Hospital
    New Taipei City, Taiwan 10002, Taiwan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2020 to primary completion in Aug 2026, 70 months.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Aug 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2019
First posted
Jan 23, 2019
StartActual
Oct 6, 2020
Primary completionActual
Aug 14, 2026
CompletionEst.
Aug 14, 2026was Dec 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Withdrawn Due to business considerations and challenges in participant recruitment, the Sponsor has decided to discontinue the study.
changed Oct 2, 2026
Sites
1 site added, 1 site removed
Show site
  • National Taiwan University Hospital · New Taipei City, Taiwan
Show 1 removed
  • National Taiwan University Hospital · New Taipei City, Taiwan
Oct 2, 2026
Primary completion
Aug 30, 2026→Aug 14, 2026 (actual)
Oct 2, 2026
Study completion
Dec 30, 2026→Aug 14, 2026
Oct 2, 2026
Enrollment
50 (estimated)→0 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Withdrawn
    Why stopped Due to business considerations and challenges in participant recruitment, the Sponsor has decided to discontinue the study.
    1 site added, 1 site removed
    Show site
    • National Taiwan University Hospital · New Taipei City, Taiwan
    Show 1 removed
    • National Taiwan University Hospital · New Taipei City, Taiwan
    Primary completion Aug 30, 2026→Aug 14, 2026 (now actual)
    Study completion Dec 30, 2026→Aug 14, 2026
    Enrollment 50 (estimated)→0 (actual)
    + 6 other changes: identifiers, verification date, oversight details, criteria formatting, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03812874
Lead sponsor
TCM Biotech International Corp.
Responsible party
Sponsor
First posted
Jan 23, 2019
Start date
Oct 6, 2020
Primary completion
Aug 14, 2026
Completion
Aug 14, 2026 (estimated)
Last update
Oct 2, 2026

Study contacts

Chien-Hung Chien-Hung, MD, PhD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion